Eli Lilly reduces Zepbound's starting price to $299 monthly, intensifying its price war with Novo Nordisk's Ozempic and Wegovy. New discounts aim to expand access to blockbuster weight-loss drugs.
Eli Lilly's oral GLP-1 drug Orforglipron offers needle-free weight management with significant results in Phase 3 trials. Discover how this tablet alternative works.
Exclusive interview with Lilly Singh on sisterhood, digital creators' respect, Hollywood diversity struggles, and why women comedians face unfair criticism. Read her powerful insights!
Eli Lilly's daily pill orforglipron shows 12% weight loss in trials, potentially revolutionizing obesity treatment. Could this be the end of injections?
Novo Nordisk and Eli Lilly develop daily oral weight loss pills with 10-16% average weight loss in trials. Pending FDA approval, these could replace injections.
Missouri Tigers QB Beau Pribula is set to start against Oklahoma Sooners just four weeks after a dislocated ankle injury. Coach Drinkwitz confirms his availability for the pivotal road game.
Eli Lilly makes pharmaceutical history as first company to achieve $1 trillion market capitalization after shares rose 1.7% on November 21, 2025. Learn what this means for investors.
Eli Lilly's Alzheimer's drug donanemab gets Indian regulatory approval. The treatment slows cognitive decline by 35.1% and could be available next year. Learn about its benefits and pricing.
Eli Lilly's Alzheimer's drug donanemab gets Indian regulator nod. The treatment slows cognitive decline by 35.1% and is expected to launch in India next year. Details on pricing and safety.
Novo Nordisk reduces Wegovy's price to $349 and prepares an aggressive launch for its oral weight-loss pill to combat competition from Eli Lilly and expand patient access.
Cobra Kai's Jacob Bertrand reveals if his character Hawk's iconic back tattoo is real. Discover the show's fashion impact and fan reactions. Read more!
Trump administration secures obesity drug price cuts with Eli Lilly and Novo Nordisk. Medicare coverage expansion opens 30 million patient market starting April 2026. Read analysis.
Former President Donald Trump reveals groundbreaking agreement with pharmaceutical giants to dramatically reduce costs of popular weight loss medications, promising relief for millions struggling with obesity.
In a major victory for American patients, pharmaceutical titans Eli Lilly and Novo Nordisk announce significant price reductions for popular weight-loss medications after Trump's intervention.
Israel's Foreign Minister Eli Cohen emphasizes growing strategic partnership with India, highlighting shared terrorism threats and expanding cooperation in defense, technology, and agriculture during crucial diplomatic meetings.
Indian and Israeli officials held high-level talks to boost cooperation in agriculture, trade, and technology during Foreign Minister Eli Cohen's strategic visit to New Delhi, marking a new chapter in bilateral relations.
Eli Lilly is developing Orforglipron oral pills for weight loss and type 2 diabetes that could replace injections, making treatment more accessible and convenient for millions.
Pharmaceutical giant Eli Lilly raises full-year profit forecast as demand skyrockets for revolutionary weight-loss treatment Zepbound, sending shares climbing 7%.
Israeli Foreign Minister Eli Cohen embarks on crucial India visit to bolster bilateral relations, discuss defense cooperation, and address regional security concerns amid growing Middle East tensions.
Pharmaceutical giant Eli Lilly partners with NVIDIA to deploy cutting-edge AI supercomputers that will accelerate drug development and transform pharmaceutical research.
Cipla's stock faces unexpected pressure despite securing rights to manufacture and distribute Eli Lilly's revolutionary weight loss drug Mounjaro in India. Discover why investors remain cautious.
In a groundbreaking move, Eli Lilly partners with Cipla to dramatically expand availability of innovative weight loss therapies across India, addressing the growing obesity crisis.
Indian pharmaceutical giant Cipla announces landmark deal with Eli Lilly to manufacture and distribute popular weight loss medications Mounjaro and Zepbound in India under different brand names.
Pharma giant Eli Lilly collaborates with Indian partner Cipla to introduce groundbreaking obesity and diabetes treatments Mounjaro and Yurpeak in the Indian market, expanding access to innovative weight management solutions.